89Bio Inc (ETNB) Stock Price, Quote & News

Company Profile

89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. The company was founded in 2018 and is headquartered in San Francisco, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 415 432 9270

Website: www.89bio.com

Address:

655 Montgomery Street, Suite 1500, San Francisco, United States

Letsinvest2024 Oct. 19 at 2:34 AM

$TPST $ETNB $RANI It’s time for $TPST 🥳

0 · Reply

biostock Oct. 10 at 5:28 AM

AI summary of $SGMT 's FASN Inhibitor VS $AKRO $ETNB 's FGF21 Analogs in MASH. $QQQ $SPY Under the radar, under valued stock.

1 · Reply

biostock Oct. 9 at 10:40 PM

$SGMT Stocks needs to 10X from here to reach at half of recent valuation paid for $ETNB and $AKRO buyout. $QQQ $SPY Let that sink in.

0 · Reply

IPOARMY1 Oct. 9 at 8:10 PM

$ALGS they're buying up the MASH drugs $NVO $AKRO $ETNB

0 · Reply

Tdorsey1776 Oct. 9 at 7:08 PM

$ETNB Tender offer accepted, shares are gone and CVR placeholder is in my account. GLTA

0 · Reply

biostock Oct. 9 at 2:08 PM

$SGMT Send it to 100 after $ETNB and $AKRO buyout. $SPY $QQQ

0 · Reply

biostock Oct. 8 at 1:13 AM

$SGMT Massive disconnect in market cap from Billions in TAM in ACNE and MASH. Roche paid billions for $ETNB MASH assets $XBI $QQQ $SPY

0 · Reply

Power2k Oct. 6 at 8:35 PM

$VKTX We are worth more than $MTSR and $ETNB combined, period. $PFE $RHHBY

1 · Reply

dogDazeSummer Oct. 6 at 5:07 PM

RA Capital absolutely crushing it with $ASND 10,107,104 or 16% of outstanding shares whereby it represents 29.9% of portfolio and making ATH today at $213 up another 4% today. RA’s 20,013,733 shares of $ETNB bought out last month And 4 of their portfolio companies ironically got sold to $ABBV during last 12 months And of course the newest position $IFRX

0 · Reply

GPTInsights Oct. 6 at 3:11 PM

$VKTX Viking MC should at least be more in line with the combination of both Metsera and 89bio purchases (~$10.5 billion) which would be over 200% from todays price. This is not even taking into account having the BIC obesity pipeline which should fetch an even higher premium. - $PFE - $MTSR deal equates to over $7 billion. - Viking MC as of today ~3 billion - Viking pipeline further along in regulatory (SC PH3, PO end of PH2, VK2809 completed PH2) - Viking assets demonstrate BIC efficacy and tolerability (SC proved this and PO showed it in PH1/should solidify evidence with PH3 after aggressive PH2 experimental study) - Viking has more cash than MTSR and 89bio - MTSR MASH asset in preclinical/discovery. - 89bio $ETNB MASH/liver assets purchased in deal worth up to $3.5 billion - VK2809 considered to be more effective than 89bio assets

1 · Reply

My Top 3 Pharma Stocks

AKRO BMY LLY MRK NVO PFE SPY

Oct 6, 2025, 5:10 PM EDT - 18 days ago

89bio Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNB

Sep 19, 2025, 12:53 PM EDT - 5 weeks ago

3 Potential Biotech Acquisition Targets

AZN INCY MLYS SNDX TVTX

Sep 19, 2025, 12:24 PM EDT - 5 weeks ago

89BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNB

Sep 18, 2025, 12:34 PM EDT - 5 weeks ago

Roche To Acquire 89bio For $2.4 Billion In Liver And Cardiometabolic Push

Sep 18, 2025, 1:29 AM EDT - 5 weeks ago

Roche to Buy 89bio for Up to $3.5 Billion

Sep 18, 2025, 1:18 AM EDT - 5 weeks ago

Roche to acquire liver drug developer 89bio for up to $3.5 billion

Sep 18, 2025, 1:02 AM EDT - 5 weeks ago

89bio, Inc. Announces Agreement to be Acquired by Roche

Sep 9, 2025, 10:09 AM EDT - 6 weeks ago

89bio, Inc. (ETNB) Presents At Cantor Global Healthcare Conference 2025 (Transcript)

Sep 5, 2025, 4:05 PM EDT - 7 weeks ago

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 3, 2025, 3:05 PM EDT - 7 weeks ago

89bio, Inc. (ETNB) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 28, 2025, 4:05 PM EDT - 2 months ago

89bio to Participate in Upcoming Investor Conferences

Aug 11, 2025, 8:22 AM EDT - 2 months ago

89bio: Promising As Pegozafermin Nears Phase 3 Readout

Aug 7, 2025, 4:05 PM EDT - 2 months ago

89bio Reports Second Quarter 2025 Financial Results and Corporate Updates

Jun 4, 2025, 4:05 PM EDT - 5 months ago

89bio to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

May 1, 2025, 4:05 PM EDT - 6 months ago

89bio Reports First Quarter 2025 Financial Results and Corporate Updates

Apr 18, 2025, 4:46 AM EDT - 6 months ago

89bio: A Buy With Strong Market Opportunity In MASH And SHTG

Mar 3, 2025, 4:05 PM EST - 8 months ago

89bio to Participate in the Leerink Partners Global Healthcare Conference

Feb 27, 2025, 4:05 PM EST - 8 months ago

89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Jan 30, 2025, 6:05 AM EST - 9 months ago

89bio's Pegozafermin Is Now Gaining Momentum

Jan 28, 2025, 10:31 PM EST - 9 months ago

89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Jan 27, 2025, 4:12 PM EST - 9 months ago

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Jan 13, 2025, 6:08 PM EST - 10 months ago

89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward

Nov 15, 2024, 8:05 AM EST - 1 year ago

89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024

Nov 12, 2024, 11:58 PM EST - 1 year ago

89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Nov 5, 2024, 4:05 PM EST - 1 year ago

89bio to Participate in the UBS Global Healthcare Conference

Oct 15, 2024, 8:30 AM EDT - 1 year ago

89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024

Sep 30, 2024, 4:05 PM EDT - 1 year ago

89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference

Sep 16, 2024, 4:05 PM EDT - 1 year ago

89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer

Aug 7, 2024, 1:59 PM EDT - 1 year ago

89bio: Bullish In Light Of Further MOA Being Established By Peer

Aug 7, 2024, 8:00 AM EDT - 1 year ago

89bio Appoints Francis Sarena as Chief Operating Officer

Aug 5, 2024, 4:05 PM EDT - 1 year ago

89bio Reports Second Quarter 2024 Financial Results and Corporate Updates

May 23, 2024, 6:32 AM EDT - 1 year ago

89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy

May 22, 2024, 4:05 PM EDT - 1 year ago

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress

May 14, 2024, 8:00 AM EDT - 1 year ago

89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis

May 9, 2024, 4:05 PM EDT - 1 year ago

89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024, 4:05 PM EDT - 1 year ago

89bio to Participate in the BofA Securities 2024 Health Care Conference

May 2, 2024, 4:05 PM EDT - 1 year ago

89bio to Host Key Opinion Leader Webinar on Pegozafermin's Opportunity in Advanced MASH

Apr 17, 2024, 4:05 PM EDT - 1 year ago

89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors

Mar 27, 2024, 8:00 AM EDT - 1 year ago

89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

Mar 12, 2024, 8:00 AM EDT - 1 year ago

89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis

Mar 8, 2024, 4:05 PM EST - 1 year ago

89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 5, 2024, 4:05 PM EST - 1 year ago

89bio to Participate in the Leerink Partners Global Biopharma Conference

Feb 29, 2024, 4:05 PM EST - 1 year ago

89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Feb 6, 2024, 4:05 PM EST - 1 year ago

89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Dec 12, 2023, 7:30 AM EST - 2 years ago

89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Dec 7, 2023, 7:00 AM EST - 2 years ago

89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Dec 6, 2023, 6:59 PM EST - 2 years ago

89bio: Despite Peer Trial Setback, Potential Remains In NASH

Letsinvest2024 Oct. 19 at 2:34 AM

$TPST $ETNB $RANI It’s time for $TPST 🥳

0 · Reply

biostock Oct. 10 at 5:28 AM

AI summary of $SGMT 's FASN Inhibitor VS $AKRO $ETNB 's FGF21 Analogs in MASH. $QQQ $SPY Under the radar, under valued stock.

1 · Reply

biostock Oct. 9 at 10:40 PM

$SGMT Stocks needs to 10X from here to reach at half of recent valuation paid for $ETNB and $AKRO buyout. $QQQ $SPY Let that sink in.

0 · Reply

IPOARMY1 Oct. 9 at 8:10 PM

$ALGS they're buying up the MASH drugs $NVO $AKRO $ETNB

0 · Reply

Tdorsey1776 Oct. 9 at 7:08 PM

$ETNB Tender offer accepted, shares are gone and CVR placeholder is in my account. GLTA

0 · Reply

biostock Oct. 9 at 2:08 PM

$SGMT Send it to 100 after $ETNB and $AKRO buyout. $SPY $QQQ

0 · Reply

biostock Oct. 8 at 1:13 AM

$SGMT Massive disconnect in market cap from Billions in TAM in ACNE and MASH. Roche paid billions for $ETNB MASH assets $XBI $QQQ $SPY

0 · Reply

Power2k Oct. 6 at 8:35 PM

$VKTX We are worth more than $MTSR and $ETNB combined, period. $PFE $RHHBY

1 · Reply

dogDazeSummer Oct. 6 at 5:07 PM

0 · Reply

GPTInsights Oct. 6 at 3:11 PM

1 · Reply

Tdorsey1776 Oct. 3 at 3:03 PM

$ETNB Has anyone received tender offer from Roche for ETNB shares?

1 · Reply

Power2k Oct. 3 at 1:24 PM

$VKTX The 3.5B takeover deal between $RHHBY and $ETNB took almost 3 yrs to mature, the Viking deal may even take much longer (4-5 yrs) considering a much higher TAM of the Obesity space, and we're a 3Billion company already. BL and the board members are working their butts off talking with multiple potential suitors and due diligences are conveyed between both parities almost on a daily basis. So let's be patient as the team is trying their best to get the company and us shareholders the deal as best as possible.

2 · Reply

Power2k Oct. 3 at 12:44 PM

$AKRO $ETNB "On January 27, 2025, Akero Therapeutics, Inc. reported positive clinical trial results from a Phase 2b clinical trial in patients with compensated cirrhosis (fibrosis stage F4) due to MASH, which contributed to heightened industry focus on the FGF21 class of therapeutics and the fibrosis stage F4 segment. Shortly thereafter, representatives of Parent conveyed that Akero Therapeutics, Inc.’s data were a positive indicator for the class and that Parent wished to assemble a cross-functional team to engage in diligence with the intent of exploring a potential collaboration with 89bio." Are those Parties terminated talks with 89bio are in talks with Akero now? Man, we can't be just a "positive indicator", we are a major player in the MASH field. $VKTX $RHHBY https://www.fiercebiotech.com/biotech/after-courting-14-pharmas-89bio-was-left-between-roche-and-hard-place-buyout-talks

0 · Reply

SweepCastApp Oct. 2 at 8:24 AM

$ETNB: Unusual Options Activity Alerted PUT flow observed 5000x contracts at Strike price of $14 Exp on 11/21/2025 with Premium of $100K and showing BEARISH Sentiment

0 · Reply

warrants_Moon Oct. 1 at 6:36 PM

$AKRO $ETNB you guys might want to check out $VKTX

1 · Reply

Tdorsey1776 Oct. 1 at 4:15 PM

$ETNB Bought another 5k yesterday ETNB @ $14.70 (paying .20 for the CVRs) So, Im betting $2K with the chance to make $60,000. $14.50 per share in cash at closing. In addition, 89bio's stockholders will receive a non-tradeable CVR to receive up to an aggregate of $6.00 per share in cash, for a total transaction equity value of up to approximately $3.5 billion on a fully diluted basis. Each non-tradeable CVR will entitle its holders to receive the following contingent cash payments, conditioned upon the achievement of certain milestones, within specified time periods: $2.00 per share in cash, upon the first commercial sale of pegozafermin in F4 MASH cirrhotic patients (by March 31, 2030) $1.50 per share in cash, upon pegozafermin reaching annual net sales globally of at least US $3.0 billion in any calendar year (by December 31, 2033) $2.50 per share in cash, upon pegozafermin reaching annual net sales globally of at least US $4.0 billion in any calendar year (by December 31, 2035)

2 · Reply

BioRich Oct. 1 at 1:22 PM

$ALT Morning Reality Check (The Dreaded Chart): If you have invested in $GUTS a month ago, you'd have a better return than 2 companies that got bought out ($MTSR and $ETNB) and a 60+% gain over $ALT. When I suggest that $ALT is dead and folks are better suited taking the tax loss and investing in $GUTS, I wasn't kidding. You would have made all of your money back, rather than pumping the next hopeful event. Reality is not your friend $ALT'ers. Listen, learn and act. Holding on to your bags for emotional and group therapy reasons isn't going to make you Rich. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some money. Cheers! $XBI

0 · Reply

OnlyFibs Sep. 29 at 9:30 PM

RECAP 9/29 Unusual Puts: $OXY Dec 43.5 P $ETNB Nov 14 P $VZ Mar 37 P

0 · Reply

OpenOutcrier Sep. 29 at 8:01 PM

RECAP 9/29 Unusual Puts: $OXY Dec 43.5 P $ETNB Nov 14 P $VZ Mar 37 P Live Breaking trading news www.openoutcrier.com

0 · Reply

CalculatedSwing Sep. 27 at 9:36 PM

$GLMD $GLMD 🚀 Don’t sleep on this NASH play! Holding strong for Q4 catalysts: Aramchol Phase 3 data drop (AASLD or Nov earnings) + new patent to 2039 w/ Rezdiffra combo potential. $50B NASH market awaits. Analysts scream BUY ($6.50–$17 targets). Tariffs? Pre-commercial, so minimal hit. MACD flipped bullish, dip to $1.20 = buy zone. 💪 Join the ride w/ $GILD $MRTX $VKTX $ETNB #biotech

1 · Reply

Tdorsey1776 Sep. 26 at 2:44 PM

$ETNB B 5k ETNB @ $14.70 (paying .20 for the CVRs) $14.50 per share in cash at closing, representing an aggregate payment of $2.4 billion. In addition, 89bio's stockholders will receive a non-tradeable CVR to receive up to an aggregate of $6.00 per share in cash, for a total transaction equity value of up to approximately $3.5 billion on a fully diluted basis. Each non-tradeable CVR will entitle its holders to receive the following contingent cash payments, conditioned upon the achievement of certain milestones, within specified time periods: $2.00 per share in cash, upon the first commercial sale of pegozafermin in F4 MASH cirrhotic patients (by March 31, 2030) $1.50 per share in cash, upon pegozafermin reaching annual net sales globally of at least US $3.0 billion in any calendar year (by December 31, 2033) $2.50 per share in cash, upon pegozafermin reaching annual net sales globally of at least US $4.0 billion in any calendar year (by December 31, 2035)

1 · Reply

namv Sep. 25 at 9:59 PM

$PFE $ROCM $ETNB $MTSR everyone getting bought up in the weight loss and mash sector… don’t get left behind get into $ALT before it’s too late

0 · Reply

Market Cap	2.19B
Revenue (ttm)	0.00
Net Income (ttm)	-367.08M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.07

Volume	3,296,200
Avg Vol	5,113,408
Day's Range	N/A - N/A
Shares Out	148.31M
Stochastic %K	45%
Beta	1.27
Analysts	Sell
Price Target	$31.64